The FDA approval of lenacapavir as a form of preexposure prophylaxis (PrEP) is a major step for HIV prevention, but its ...

WHO endorses biannual injectable Lenacapavir for HIV prevention. This long-acting PrEP offers hope for high-risk groups and ...

The FDA approved Gilead's HIV prevention drug lenacapavir, a twice-a-year injectable medication that clinical trials show prevents new infections.

As expected, the new recommendations that the World Health Organization (WHO) issued for HIV and sexually transmitted ...

Lenacapavir is the latest HIV prevention shot to receive FDA approval. Apretude , made by GSK’s ViiV Healthcare, was the first injectable pre-exposure prophylaxis medication to receive approval ...

The Food and Drug Administration (FDA) recently approved lenacapavir for HIV prevention in both men and women. Many experts believe this twice a year treatment could be a game changer in the fight ...

The injectable HIV prevention treatment Yetzugo, made by Gilead Sciences, has received FDA approval, offering a twice-yearly ...

Clinical trials have shown that six-monthly injections of lenacapavir are almost 100 percent protective against becoming infected with HIV. But big questions remain over the drug’s affordability.

The FDA's decision makes lenacapavir available today in the U.S., which sees about 31,000 of the 1.3 million new HIV infections each year worldwide.

Gilead Sciences submitted a new drug application to the FDA for the approval of lenacapavir, an investigational, long-acting HIV-1 capsid inhibitor that is given subcutaneously every 6 months.

Kenya is set to roll out the long-acting injectable HIV Pre-Exposure prophylaxis (PrEP) Lenacapavir by January 2026 following ...